MindMed
About MindMed
MindMed is a clinical-stage biopharmaceutical company dedicated to developing innovative psychedelic-inspired therapies for brain health disorders. Leveraging cutting-edge research, MindMed focuses on conditions such as anxiety, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorder. Their robust pipeline includes MM-120, a proprietary form of LSD targeting generalized anxiety disorder, and MM-402, the R-enantiomer of MDMA, aimed at treating core symptoms of autism spectrum disorder. Committed to advancing mental health treatment, MindMed combines scientific expertise with a patient-centric approach to deliver transformative therapies that address significant unmet needs.
MindMed Is Now Dosing Patients In Phase III Clinical Trial For LSD
MindMed (NASDAQ: MNMD) has officially begun dosing the first patients in their Phase III clinical trial for MM120 ODT for the treatment of generalized anxiety.
MindMed Receives Breakthrough Therapy Designation From FDA For LSD
Psychedelic biotechnology company MindMed (NASDAQ: MNMD) has received a Breakthrough Therapy designation from the United States FDA for their novel drug MM120.
